Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nesiritide during extracorporeal membrane oxygenation.

Todd Smith1, David A Rosen, Pierantonio Russo

  • 1Department of Anesthesiology, University of Missouri, Columbia, MO 65212, USA.

Paediatric Anaesthesia
|January 29, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Molecular response to the non-lytic peptide bac7 (1-35) triggers disruption of Klebsiella pneumoniae biofilm.

PLoS pathogens·2026
Same author

Ruptured Pulmonary Echinococcus Cyst.

Journal of the Pediatric Infectious Diseases Society·2026
Same author

Sedation Protocols: Is the Mind Willing and the Body Weak or Vice Versa?

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·2026
Same author

Differential contributions of ClpX and ClpP to pulmonary virulence in classical and hypervirulent <i>Klebsiella pneumoniae</i>.

Infection and immunity·2026
Same author

Case 2-2026: A 63-Year-Old Man with Pulmonary Nodules, Liver Mass, and Vision Loss.

The New England journal of medicine·2026
Same author

A multivalent capsule vaccine protects against Klebsiella pneumoniae bloodstream infections in healthy and immunocompromised mice.

NPJ vaccines·2025

Nesiritide, a B-type natriuretic peptide (BNP) formulation, shows potential in infants undergoing extracorporeal membrane oxygenation (ECMO). This study explored its use for blood pressure control and urine output augmentation in pediatric ECMO patients.

Area of Science:

  • Cardiovascular Physiology
  • Pediatric Critical Care
  • Pharmacology

Background:

  • Nesiritide is a recombinant B-type natriuretic peptide (BNP) effective in adult decompensated congestive heart failure (CHF).
  • Its physiological effects suggest potential utility beyond adult CHF, including in critical pediatric care settings.
  • Extracorporeal membrane oxygenation (ECMO) is a life support therapy for critically ill infants with cardiorespiratory failure.

Observation:

  • This report details the use of nesiritide in two infants receiving ECMO.
  • Nesiritide was administered at varying doses to manage specific clinical issues during ECMO support.

Findings:

  • In one infant, nesiritide (up to 0.09 microg.kg(-1).min(-1)) helped control mean arterial pressure.
  • In the second infant, lower doses (0.01-0.03 microg.kg(-1).min(-1)) were used to increase urine output.

Related Experiment Videos

Implications:

  • Nesiritide demonstrates potential as a therapeutic agent in infants undergoing ECMO.
  • Further research is warranted to establish optimal dosing regimens and efficacy for nesiritide in the pediatric ECMO population.
  • This case series may guide future clinical applications of nesiritide in neonates and infants requiring advanced cardiorespiratory support.